Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non‐responders: Double‐blinded, randomised, controlled phase 2 trial

BACKGROUND & AIMS: Approximately 5%–10% of the general population respond inadequately to licensed recombinant hepatitis B vaccines. We assessed the immunogenicity and safety of a new HBAI20 vaccine, consisting of a new AI20 adjuvant (20‐µg recombinant human IL‐2 attached to 20‐µg aluminium hydr...

Descripción completa

Detalles Bibliográficos
Autores principales: Koc, Özgür M., de Smedt, Philippe, Kremer, Cécile, Robaeys, Geert, van Damme, Pierre, Hens, Niel, Almeida, Jorge, Falkenberg, Frank, Savelkoul, Paul, Oude Lashof, Astrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518051/
https://www.ncbi.nlm.nih.gov/pubmed/33966331
http://dx.doi.org/10.1111/liv.14939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518051/
https://www.ncbi.nlm.nih.gov/pubmed/33966331
http://dx.doi.org/10.1111/liv.14939

Ejemplares similares